A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)

The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Behavior

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Smoking greater than/equal to 10 cigarettes/day for at least 1 year
Laboratory tests that meet the criteria of the study
In overall good health as determined by the investigator

Exclusion criteria

Psychiatric diagnoses
Certain cancers
Patients who use nicotine replacement therapy
Patients on a diet regimen

Treatment and study plan

taranabant

Drug

Other names: MK0364

Primary outcomes

Quitting smoking after 8 weeks of treatment by measuring lab values and expired breath CO levels

Time frame: after 8 weeks of treatment

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Double-Blind, Multicenter, Randomized, Titrated-Dose, Placebo-Controlled, Study of MK0364 (4 mg to 8 mg) in Chronic Cigarette Smokers as an Aid for Smoking Cessation

Important dates

Study start: 2005
Primary completion: 2005
Study completion: 2005
First posted: Apr 25, 2005
Registry last updated: Sep 25, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed